Evidence map›Paper›PMID 40552123›Full record

ArticleFrontiers in cellular and infection microbiology2025

A comprehensive evaluation of a novel targeted-sequencing workflow for

Xichao Ou, Shaojun Pei, Hongru Li, Zhonghua Qin, Richard Anthony, Jichun Wang, Zexuan Song, Ruida Xing, Lixia Zhang, Chong Teng and 7 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xichao Ou *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Shaojun Pei *National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Hongru Li *Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhonghua Qin *Center for Accurate Detection of Tuberculosis, Tianjin Haihe Hospital, Tianjin, China.
Richard AnthonyCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
Jichun WangDepartment of Science and Technology, Chinese Center for Disease Control and Prevention, Beijing, China.
Zexuan SongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Ruida XingNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Lixia ZhangCenter for Accurate Detection of Tuberculosis, Tianjin Haihe Hospital, Tianjin, China.
Chong TengDepartment of Tuberculosis, Beijing Dongcheng District Center for Disease Control and Prevention, Beijing, China.
Hui XiaNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yang ZhouNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuanyuan SongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yang ZhengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Shengfen WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Bing ZhaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yanlin ZhaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although several World Health Organization-endorsed targeted next-generation sequencing (tNGS) assays exist for tuberculosis (TB) drug-resistance detection, their target selection and diagnostic accuracy vary widely. In this study, we developed a novel tNGS workflow (the TB Pro assay) and evaluated its performance in identifying Methods: The TB Pro assay was validated for identifying 10 Results: The assay demonstrated high sensitivity with a calculated LOD of 3.0 CFU/ml for MTB and 1.4-16.2 CFU/ml for most NTMs, except for Conclusions: The TB Pro assay represents a sensitive and specific solution for simultaneous mycobacterial identification and comprehensive drug-resistance profiling, performing robustly on both cultured isolates and direct clinical specimens.

Indexed as

Antitubercular AgentsDrug Resistance, BacterialHigh-Throughput Nucleotide SequencingMycobacteriumMycobacterium tuberculosisNontuberculous MycobacteriaTuberculosis, Multidrug-ResistantHumansLimit of DetectionMicrobial Sensitivity TestsSensitivity and SpecificitySputumTuberculosisWhole Genome SequencingWorkflowAntitubercular Agentsdrug resistancemultiplex PCR (polymerase chain reaction)Mycobacterium tuberculosisnon-tuberculous mycobacteriosistargeted next generation sequencing (tNGS)

Identifiers

PMID40552123
PMCPMC12183266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.